Welcome to our dedicated page for Innovent Biologi news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologi stock.
The news feed for INNOVENT BIOLGCS UNSP/ADR (IVBIY) aggregates company press releases and media updates from Innovent Biologics, Inc., a biopharmaceutical company focused on oncology, cardiovascular and metabolic, autoimmune and ophthalmology diseases. These announcements provide insight into clinical trial progress, regulatory milestones, product approvals and corporate strategy that can influence how investors and observers view IVBIY.
Recent news highlights include multiple updates on mazdutide, a dual GCG/GLP-1 receptor agonist licensed from Eli Lilly for development in China. Innovent has reported National Medical Products Administration approvals for mazdutide in chronic weight management for adults with overweight or obesity and for glycemic control in adults with type 2 diabetes, along with Phase 3 data from the GLORY and DREAMS clinical programs. Other cardiovascular and metabolic pipeline news covers tigulixostat, a xanthine oxidase inhibitor for gout, and IBI3032, an oral GLP-1 receptor agonist with U.S. FDA IND approval for Phase 1 trials.
Oncology news items describe the development of IBI363, a PD-1/IL-2α-bias fusion protein, including U.S. FDA clearance of an IND for a global Phase 3 trial in immunotherapy-resistant squamous non-small cell lung cancer and data presented at major oncology conferences. Additional coverage includes IBI343, an anti-CLDN18.2 ADC with Phase 1 results in gastric/gastroesophageal junction adenocarcinoma published in Nature Medicine and the launch of multi-regional Phase 3 studies.
Investors following IVBIY can use this page to review updates on Innovent’s broader pipeline, such as picankibart for psoriasis, IBI324 for retinal diseases, and other marketed products mentioned in interim results and R&D day communications. Bookmark this news section to monitor how clinical data releases, regulatory decisions and partnership announcements may shape the company’s long-term development and commercialization plans.
Innovent Biologics announced that the NMPA in China has granted Breakthrough Therapy Designation for Parsaclisib (IBI376) to treat relapsed/refractory follicular lymphoma. This designation is based on ongoing Phase 2 studies showcasing promising efficacy, with a 75% objective response rate and a 15.8-month median progression-free survival. Innovent, which has rights for Parsaclisib in Greater China, emphasizes its commitment to developing effective cancer therapies. The BTD status will facilitate faster review processes, advancing treatment accessibility for patients.
Innovent Biologics reported significant financial growth for 2020, achieving a total revenue of RMB 3,843.8 million, up 266.9% from RMB 1,047.5 million in 2019. The company's product revenue reached RMB 2,367.5 million, a 133.0% increase year-over-year. Innovent launched three new antibody drugs, augmenting its portfolio to four commercial products. The firm expanded its production capacity from 5,000L to 24,000L and raised approximately US$1.3 billion through share placements, with US$1.8 billion in cash on hand by February 2021.
Innovent Biologics, a biopharmaceutical company, reports the successful dosing of the first patient outside China in a Phase 1 clinical trial of IBI322, a first-in-class recombinant anti-CD47/PD-L1 bispecific antibody.
This trial, conducted in the U.S., aims to evaluate the safety, tolerability, and initial anti-tumor efficacy of IBI322 in patients with advanced malignancies. Pre-clinical studies suggest that IBI322 could offer enhanced anti-tumor activity and a better safety profile compared to existing treatments. The company aims to develop this innovative drug globally following IND approvals from NMPA and the U.S. FDA.
Innovent Biologics and IASO Biotherapeutics announced that their CAR-T cell therapy, IBI326, received Breakthrough Therapy Designation from China's NMPA. This designation, granted on Feb. 22, 2021, is based on results from an ongoing Phase 1/2 study for treating relapsed/refractory multiple myeloma. IBI326 is a fully-human CAR-T therapy targeting BCMA, showing rapid anti-myeloma activity and positive safety profiles. This designation may expedite its development and review in China, allowing earlier patient access.
Innovent Biologics has successfully dosed the first patient in a Phase III clinical trial (NCT04720716) for IBI310, an anti-CTLA-4 monoclonal antibody, in combination with TYVYT® (sintilimab injection) for advanced hepatocellular carcinoma (HCC). This multicenter trial aims to evaluate the efficacy and safety of this combination treatment, focusing on overall survival and response rate. With over 50 clinical centers involved, the study led by prominent professors is expected to provide valuable insights into new therapeutic options for HCC patients.
Innovent Biologics and Eli Lilly announced that China's National Medical Products Administration has approved TYVYT® (sintilimab injection) for treating nonsquamous non-small cell lung cancer (nsqNSCLC) in combination with pemetrexed and platinum chemotherapy. This approval follows a successful Phase 3 clinical trial (ORIENT-11) demonstrating significant improvements in progression-free survival (PFS) and overall survival (OS) for TYVYT® over placebo. This marks the second indication for TYVYT® since its initial approval for Hodgkin's lymphoma in December 2018.
Innovent Biologics has appointed Dr. Yong Jun Liu as the new president, enhancing its leadership in R&D and global operations. With over 30 years of experience, Dr. Liu has significant achievements in biotechnology, notably at AstraZeneca and Sanofi, where he led drug research initiatives. Innovent, established in 2011, has a robust pipeline of 23 assets and has approved four products in China, including TYVYT®, a PD-1 inhibitor. Dr. Liu's leadership is expected to strengthen Innovent's commitment to innovative drug development.
Innovent Biologics and Eli Lilly announced that HALPRYZA® (rituximab injection) has been approved by China's NMPA for treating non-Hodgkin's lymphoma and chronic lymphocytic leukemia. This marks Innovent's fourth monoclonal antibody approval, following TYVYT®, BYVASDA®, and SULINNO®. The drug will provide a more affordable treatment option for Chinese patients, enhancing healthcare access. With confirmed safety and efficacy in major clinical trials, HALPRYZA® aims to improve patient outcomes in a growing segment of hematological malignancies in China.
Innovent Biologics announced the expiration of the waiting period under the HSR Act, allowing its global collaboration with Eli Lilly for TYVYT® (sintilimab injection) to take effect. This milestone triggers a $200 million upfront payment. TYVYT® has received marketing approval in China for relapsed Hodgkin's lymphoma and is included in the NRDL. Innovent is actively engaged in over 20 clinical studies to assess TYVYT®'s efficacy in various cancers, bolstering its robust pipeline of oncology drugs.
Innovent Biologics, a leading biopharmaceutical company, will host a virtual R&D day on November 10, 2020, featuring two sessions: one in Mandarin from 8:00 AM to 12:00 PM and another in English from 9:00 PM to 1:00 AM (next day), both China/Singapore time. The event will cover the company's development, long-term vision, and an in-depth discussion on its R&D pipeline. Participants must register before November 8 to receive access details. Innovent is recognized for its innovative treatments, including three marketed products and a robust pipeline targeting major diseases.